Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLACIAL: Xolair in Refractory Chronic Idiopathic Urticaria
NCT01264939Phase 3Completed
- Sponsor
- Genentech
- Start
- Feb 2011
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Omalizumab 300 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants With Adverse Events at 40 weeks. Started Feb 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT01264939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01264939.